CHF and arrhythmias:
Indications for: JARDIANCE
To reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in adults with HF. To reduce the risk of cardiovascular (CV) death in adults with T2DM and established CV disease.
Adult Dosage:
Take in the AM. 10mg once daily. Insufficient data for dosing: in those who have T2DM and established CV disease (with eGFR <30mL/min/1.73m2), or those who have HF (with eGFR <20mL/min/1.73m2).
Children Dosage:
<18yrs: not established.
JARDIANCE Contraindications:
Patients on dialysis.
JARDIANCE Warnings/Precautions:
Correct volume depletion before initiating. Increased risk for volume depletion or hypotension in those with renal impairment (eGFR <60mL/min/1.73m2), elderly, or on loop diuretics. Assess volume status and renal function prior to initiation; monitor during therapy. Assess for ketoacidosis in presence of signs/symptoms of metabolic acidosis, regardless of blood glucose levels; discontinue if suspected, evaluate and treat; consider risk factors before initiation (eg, pancreatic insulin deficiency, caloric restriction, alcohol abuse). Consider temporarily discontinuing prior to scheduled surgery (for ≥3 days) or other clinical situations (eg, prolonged fasting due to illness or post-surgery). Necrotizing fasciitis of the perineum (Fournier's gangrene); discontinue and treat immediately if suspected; use alternative antidiabetic. Increased risk of genital mycotic infections or UTIs; monitor and treat appropriately. Discontinue if hypersensitivity reaction occurs; treat promptly and monitor until resolve. Elderly. Pregnancy (during 2nd & 3rd trimesters), nursing mothers: not recommended.
JARDIANCE Classification:
Sodium-glucose co-transporter 2 (SGLT2) inhibitor.
JARDIANCE Interactions:
Greater potential for volume depletion with concomitant diuretics. Consider a lower dose of concomitant insulin or insulin secretagogue (eg, sulfonylurea) to reduce risk of hypoglycemia. May antagonize serum lithium concentrations; monitor levels more frequently. May result in false (+) urine glucose tests or unreliable measurements of 1,5-AG assay; use alternative methods to monitor glycemic control.
Adverse Reactions:
UTIs, female genital mycotic infections, increased urination; hypotension, ketoacidosis, renal impairment, urosepsis, pyelonephritis, angioedema; rare: Fournier's gangrene.
Generic Drug Availability:
NO
How Supplied:
Tabs—30, 90
Diabetes:
Indications for: JARDIANCE
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).
Limitations of Use:
Not recommended in those with type 1 diabetes; may increase risk of diabetic ketoacidosis. Not recommended in adults with T2DM with an eGFR <30mL/min/1.73m2.
Adult Dosage:
Take in the AM. Initially 10mg once daily; may increase to 25mg, if tolerated.
Children Dosage:
<18yrs: not established.
JARDIANCE Contraindications:
Patients on dialysis.
JARDIANCE Warnings/Precautions:
Correct volume depletion before initiating. Increased risk for volume depletion or hypotension in those with renal impairment (eGFR <60mL/min/1.73m2), elderly, or on loop diuretics. Assess volume status and renal function prior to initiation; monitor during therapy. Assess for ketoacidosis in presence of signs/symptoms of metabolic acidosis, regardless of blood glucose levels; discontinue if suspected, evaluate and treat; consider risk factors before initiation (eg, pancreatic insulin deficiency, caloric restriction, alcohol abuse). Consider temporarily discontinuing prior to scheduled surgery (for ≥3 days) or other clinical situations (eg, prolonged fasting due to illness or post-surgery). Necrotizing fasciitis of the perineum (Fournier's gangrene); discontinue and treat immediately if suspected; use alternative antidiabetic. Increased risk of genital mycotic infections or UTIs; monitor and treat appropriately. Discontinue if hypersensitivity reaction occurs; treat promptly and monitor until resolve. Elderly. Pregnancy (during 2nd & 3rd trimesters), nursing mothers: not recommended.
JARDIANCE Classification:
Sodium-glucose co-transporter 2 (SGLT2) inhibitor.
JARDIANCE Interactions:
Greater potential for volume depletion with concomitant diuretics. Consider a lower dose of concomitant insulin or insulin secretagogue (eg, sulfonylurea) to reduce risk of hypoglycemia. May antagonize serum lithium concentrations; monitor levels more frequently. May result in false (+) urine glucose tests or unreliable measurements of 1,5-AG assay; use alternative methods to monitor glycemic control.
Adverse Reactions:
UTIs, female genital mycotic infections, increased urination; hypotension, ketoacidosis, renal impairment, urosepsis, pyelonephritis, angioedema; rare: Fournier's gangrene.
Generic Drug Availability:
NO
How Supplied:
Tabs—30, 90
